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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) is a malignant epithelial disease 
arising from the mucosa of the upper aerodigestive tract. It is the 6th most common 
malignancy worldwide with approximately 650 000 new cases diagnosed each year 
(Torre et al. 2015; Ferlay et al. 2010). It  can be localised in different anatomical sites of 
the head and neck region (oral cavity, oropharynx, nasopharynx, larynx and 
occassionally in the paranasal sinuses) (Barnes, World Health Organization, and 
International Agency for Research on Cancer 2007). Current therapy consists of 
surgical resection or radiation therapy or a combination of these methods (Sweeney et 
al. 1994), but to date survival rates remain relatively low, with a 5-year survival rate of 
around 30-40% (Vokes et al. 1993).  
In patients with HNSCC in the anamnesis, the chance of acquiring a second malignancy 
in the lung is about 5.4% according to a study carried out on 3907 patients (Atabek et al. 
1987). The differentiation between a lung metastasis of a HNSCC and a second primary 
squamous cell carcinoma of the lung (LSCC) remains one of the most difficult tasks in 
diagnostic pathology, although differentiation would be crucial because of the highly 
different therapeutic regimes in the patient groups. In most cases traditional 
morphological-immunohistochemical examinations fail to find the origin of the lung 
tumor, so that a reliable method of differentiation is desperately needed. 
The most well-known risk factors of HNSCC are tobacco and alcohol consumption and 
the prevalence of mutations of the TP53 gene is traditionally high in these tumors 
(Kropveld et al. 1999).  
However, recent research has shown that differentiation has to be made between two 
major types of HNSCC; HPV-asssociated and non-HPV-associated tumors. An 
increasing amount of HNSCC is associated with high risk HPV-serotypes (HPV-16, 18, 
31, 33, etc.). About 40-80% of HNSCC is associated with HPV-16 in the USA and 20-
90% is associated with high risk HPV in Europe (Marur et al. 2010a). HPV-associated 
HNSCC is traditionally not TP53 mutated (Westra et al. 2008), whereas in HPV 
negative HNSCC, TP53 mutations can be found in most of the cases (Kropveld et al. 
1999).  
Researchers have tried to differentiate between lung metastasis and second primary lung 
tumor comparing HPV-status of the head and neck tumor and the lung tumor. This 
approach seems to be successful in some of the cases (Weichert et al. 2009; Bishop et 
al. 2012). However, in cases of HPV negativity in both tumors, additional methods 
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should be considered. Further studies have described a number of comparative 
molecular methods to find out the origin of the lung tumor (these will be discussed in 
detail in this work later on), but an universally accepted method has not yet been 
presented. 
In the past few years, next generation sequencing technology has been established 
worldwide and also in our institute of pathology. With this technology it became easier 
and faster to analyse mutations of the TP53 gene (or other genes of interest) and to find 
out tumor origin of squamous cell carcinomas by sequencing of the TP53 exones. This 
method has the advantage, that mutations of all coding exones of the TP53 gene can be 
examined in a very time-effective high-troughput way. We hypothetised, that 
comparing the mutations of the HNSCC and LSCC can lead to a decision on lung tumor 
origin.  
The aim of this study was to analyse patients with HNSCC and 
synchronous/metachronous LSCC to decide on lung tumor origin using a combination 
of HPV-typing and targeted next generation sequencing of all coding exones of the 
TP53 gene. We analysed a total 32 cases to try and make a decision on lung tumor 
origin. Furthermore, we analysed clinical records and therapeutic data to see, in what 
way this diagnostic method might contribute to diagnostic precision and clinical 
decision making. 
1.1. Epidemiology, ethiology and pathogenesis of squamous cell 
carcinoma of the head and neck and squamous cell carcinoma of 
the lung  
1.1.1. Head and neck squamous cell carcinoma 
1.1.1.1. Epidemiology and ethiology 
Head and neck squamous cell carcinoma is the 6th most common malignancy 
worldwide responsible for more than 650 000 annual newly diagnosed cases and 
300 000 annual deaths (Parkin et al. 2005). Localisation of the tumors may be different 
(oral cavity, oropharynx, nasopharynx, larynx and occassionally in the paranasal 
sinuses) and localisation of the tumor is a relevant factor influencing survival rates.  
Traditional risk factors of HNSCC include genetic risk factors, poor oral hygiene, as 
well as tobacco and alcohol consumption. Traditional HNSCC is associated with 
mutations of the TP53 gene. 
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Recent research has shown though, that human papilloma virus infections are 
responsible for the disease in an increasing proportion of the cases. HPV has more than 
100 serotypes, which can be categorised in low risk (6, 11, 40, etc.) and high risk (16, 
18, 31, 33, etc.) serotypes and it has a well-known pathogenetic role in anogenital 
cancer, being probably most well-known for its role in the cervical cancer of the uterus. 
In HPV-associated cases, tipically younger white men at the age of 40-50 years are 
affected, who have no tobacco or alcohol consumption in their anamnesis (Marur et al. 
2010b).  
TP53 mutations and HPV-association are mutually exclusive in HNSCC in the majority 
of the cases (Westra et al. 2008). 
1.1.1.2. TP53 mutations and mutation landscape 
The p53 protein is possibly one of most frequently and longest studied proteins in the 
history of cancer research. It is also called the guardian of the genome and is 
responsible for many essential cell functions like DNA-synthesis and DNA-repair, cell 
cycle arrest and programmed cell death, as well as energy metabolism. It is the product 
of the TP53 gene.  
The TP53 gene is located on the short arm of chromosome 17 in humans (Matlashewski 
et al. 1984), it  has 11 exons of which exon 2-11 are protein coding. Most mutations of 
the gene appear on exon 5-8, coding the DNA binding domain of the p53 protein 
(Greenblatt et al. 1994), but according to literature, about 25% of the mutations can be 
found outside of these exons. Thus some authors suggest, that TP53 analysis should be 
carried out on all coding exons when searching for mutations (Hartmann et al. 1995). 
Mutations of the TP53 gene are mostly ’small mutations’ (missense and nonsense 
mutations, as well as deletions or insertions of more nucleotides) (Perri et al. 2015), as 
well as the recently reported and poorly understood gain of function mutations 
(Donzelli et al. 2008). It has been pointed out, that immunohistochemical reactions for 
the diagnosis of TP53 mutations are insufficient and they can lead to confusions 
(MacGeoch et al. 1993; Calzolari et al. 1997). Consequently, when analysing TP53 
mutations, molecular genetic methods should be preferred over immunohistochemistry.  
It has been shown in recent whole exome sequencing experiments, that adherent to the 
already known frequently mutated genes in HNSCC (TP53, HRAS, PTEN, PIK3CA, 
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CDKN2A etc), other genes, like TP63, NOTCH1  and FBXW7  might play an 
important role (Stransky et al. 2011; Agrawal et al. 2011). 
Some of the patients with HNSCC develop further carcinomas in the head and neck 
region and it has been suggested, that these tumors are clonally different from the 
primary head and neck carcinoma, containing different genetic alterations. This 
phenomenon is described by the ’field cancerisation’ theory, and suggests, that patients 
with such tumors have a high risk of developing tumors in the upper aerodigestive 
mucosa because of extensive mucosal damage. The tumors are described as independent 
events (Savary et al. 1991) and it has been pointed out, that patients with two primary 
tumors in their patient history have about 50% chance to develop a 3rd head and neck 
tumor (Savary et al. 1991).  
1.1.1.3. The role of the human papillomavirus 
The human papillomavirus has more than 100 serotypes, which can be categorised in 
low risk (6, 11, 40, etc.) and high risk (16, 18, 31, 33, etc.) serotypes. The role of HPV is 
well known in cervical cancer, but according to recent publications, the number of 
HPV-positive HNSCC compared to traditional HNSCC caused by tobacco and alcohol 
consumption, has been increasing rapidly. 
At the molecular level, HPV infection leads to the degradation of the p53 protein and 
the inactivation of the retinoblastoma pathway as well as to an upregulation of the p16 
protein. The virus first integrates in the human DNA and causes dysregulation with two 
proteins named E6 and E7. The E6 protein leads to the ubiquitin-mediated proteolysis 
of the p53 protein, whereas E7 binds to pRB, a product of the retinoblastoma tumor 
suppressor gene and inactivates it (Wiest et al. 2002). The p53 protein leads to cell 
cyclus arrest or apoptosis in case of a transcriptional mistake, unless the DNA is 
repaired. Degradation of this protein inevitably leads to genomic instability. 
Furthermore, the E7 protein inactivates pRB and it causes the cell to enter into the S-
phase and thus causes uncontolled proliferation and malignant transformation of the cell 
(Wiest et al. 2002).  
There is an essential need for routine testing of HPV-positivity in HNSCC, because of 
the better prognosis of HPV-positive tumors. However, finding an appropriate method 
for testing is not self-evident. There are multiple possible methods, as type-specific 
PCR-methods, in situ DNA hybridisation methods, real-time PCR methods or p16 
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immunohistochemistry. According to literature a combination of p16 
immunohistochemistry (100% specificity) and HPV in situ hybridization (nearly 100% 
sensitivity) leads to highly accurate information on HPV-association (Marur et al. 
2010). 
1.1.2. Squamous cell carcinoma of the lung 
1.1.2.1. Epidemiology and ethiology 
According to the definition of the World Health Organisation, ’squamous cell 
carcinoma (SCC) is a malignant epithelial tumor showing keratinization and/or 
intercellular bridges that arises from bronchial epithelium’ (Travis et al. 2004). In men 
44%, whereas in women 25% of lung cancer is squamous cell carcinoma. In 2012 more 
than 1.6 million deaths were caused by lung cancer and expectations are, that this 
number grows to 3 million by 2035. Although a century ago, cancer of the lung was 
extremely rare, now it is the most frequent cause of death of all cancers (Didkowska et 
al. 2016).  
Numerous risk factors have been inquired (asbestos, nickel, coal-tars, dioxin, etc.) in 
connection with lung cancer, but their effects are not to be compared with the most 
important risk factor of all, tobacco smoking.  Decline of mortality and incidence has 
started in some countries (UK, USA, etc.) in the 1970s but some other countries 
(Hungary, Poland, etc.) are still having increasing incidence and mortality rates.  
Lung cancer can be subdivided in small cell lung cancer (SCLC) and in non-small cell 
lung cancer (NSCLC) – including squamous cell carcinoma, adenocarcinoma, large cell 
carcinoma, adenosquamous carcinoma and sarcomatoid carcinoma (Rosai and 
Ackerman 2011). 
Histological classificiation of squamous cell carcinoma of the lung according to the 
WHO: 
1. Squamous cell carcinoma 
2. Papillary carcinoma 
3. Clear cell carcinoma 
4. Small cell carcinoma 
5. Basaloid carcinoma.  
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1.1.2.2. Mutations in squamous cell lung cancer 
Mutation profiles of lung cancer depend on histological type. There are characteristic 
mutations in NSCLC, which originate from the epithelial cells of bronchi and alveoli, as 
well as in SCLC, originating from epithelial cells of the lung with neuro-endocrine 
features. Furthermore, there are differences in mutation profiles of squamous cell 
carcinoma and adenocarcinoma. However, some of the mutations appear in most lung 
cancers independent of histology. These are p53 mutations, mutations of the 
retinoblastoma pathway and loss of heterozygosity (LOH) on the chromosome 3p 
(Travis et al. 2004). Mutations of the TP53 gene can be found in about 50% of the cases 
(Pfeifer et al. 2002). 
Mutations of the retinoblastoma pathway can have different reasons, such as CDKN2A 
silencing (the gene encoding p16), RB1 expression loss or CCND1 (encoding cyclin 
D1) overexpression (Brambilla et al. 1999). 
Finally, LOH on the chromosome 3p affects many, yet poorly understood tumor 
suppressor genes (FHIT, RASSF1, SEMA3B) (Lerman and Minna 2000; Lu et al. 
1999). This mutation can be found in about 80% of NSCLC (Brauch et al. 1987). 
Overexpression of the epidermal growth factor (EGFR) can be seen in virtually all 
squamous cell carcinomas (Franklin et al. 2002), whereas Her2/neu expression and RAS 
mutations are rather rare (Travis et al. 2004). 
The EGFR  is expressed in 84% of squamous cell carcinomas of the lung (Herbst 2004). 
EGFR is responsible for cell survival, proliferation and metastasis and it is associated 
with chemotherapy and radiotherapy resistance (Iliakis 1997), but is also an important 
target of targeted molecular therapies (Mendelsohn and Dinney 2001).  
1.2. Morphological and immunohistochemical aspects in squamous 
cell carcinoma 
Squamous cell carcinomas (SCC) can be divided in two groups morphologically: 
keratinizing and non-keratinizing carcinomas (Chernock 2012). Squamous cell 
carcinomas have the same morphological and immunohistochemical profile 
independent on tumor origin (Hayashi et al. 2013; Dotto and Rustgi 2016). The tumors 
stain positive for the pancytokeratin markers like MNF116 and AE1/AE3  as well as for 
CK5/6 and partly for cytokeratin 7 (Pulitzer, Desman, and Busam 2010). A squamous 
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cell specific marker, P40 has been recently established in pathological diagnostics. It is 
a nuclear antigen, that is specifically expressed in normal squamous cell epithelium and 
also in squamous cell carcinomas (Nobre, Albergaria, and Schmitt 2013; Ha Lan et al. 
2014). It is important to point out, that the origin of the SCC can not be assessed by the 
use of this marker. Both HNSCC, its metastases and also primary squamous cell 
carcinomas of other primaries (lung, skin, etc.) stain positive for P40 (Alomari, Glusac, 
and McNiff. 2014). 
1.3. Therapeutic considerations and survival rates 
1.3.1. Therapy of squamous cell carcinoma of the head and neck 
HNSCC therapy depends on many factors, such as localisation of the tumor, 
resectability, TNM stadium, operability and general condition of the patient, 
comorbidities and evidently the preferations of the patient, etc. It is always important 
that the therapy is discussed at tumor conferences, where, as a result of a 
multidisciplinary discussion, the best possible therapy can be chosen.  
When considering therapy, HNSCC is currently divided into three main stages, 
1. Early stage HNSCC (Stage I-II) 
2. Locally advanced HNSCC (Stage III-IV) 
3. Recurrent or metastatic disease (Pan, Gorin, and Teknos 2009). 
Therapy of early stage HNSCC as well as of metastatic diesease are not far disputed in 
the literature, it is agreed on, that early stage cancer must be treated with surgery or 
radiotherapy and in many cases of early cancer, these therapies are curative.  
Therapy of metastatic disease is in most cases platinum based palliative chemotherapy, 
which is effective in about 1/3 of the cases. If it does not bring any effect, further 
treatment options are profoundly limited (Pan, Gorin, and Teknos 2009). The overall 
survival of patients with metastatic disease is 5-9 months (Cohen, Lingen, and Vokes 
2004). 
In locally advanced diesease, therapy should always be multimodal, consisting of 
combinations of chemotherapy, radiotherapy and surgery. Chemotherapy can be used in  
neoadjuvant (before surgical resection), concurrent (simultaneously with radiotherapy) 
and adjuvant (after surgery) concepts. Although many studies have been carried out, 
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superiority of one or an other is not clear, as well as it is also not clear, whether one 
chemotherapeutic combination is better than the other. However, there is sufficient 
proof, that chemotherapy combined with radiotherapy has better results than 
radiotherapy alone in case of locally advanced disease (Pan, Gorin, and Teknos 2009). 
The most widespread chemotherapeutic agents are platinum based agents (cisplatin, 
carboplatin), and these are often combined with 5-fluorouracil (5-FU) or taxanes 
(doxetaxel, paclitaxel) (Adelstein et al. 2006; Taylor et al. 1997). 
The EGFR inhibitor cetuximab has been recently approved by the FDA for therapy of 
cisplatin resistant metastatic/recurrent HNSCC and a Phase III study (EXTREME 
study) has shown that it increases overall survival also combined with platinum based 
chemotherapy in metastatic/recurrent HNSCC. Although EGFR inhibitors are effective 
in some of the patients, finding the optimal patient eligible for EGFR inhibitor therapy 
is yet a problem (Pan, Gorin, and Teknos 2009; Jedlinski et al. 2013; Loeffler-Ragg et 
al. 2008; Vermorken et al. 2008). 
An also recently emerged question is the therapy of HPV-associated and HPV-negative 
HNSCC. Some authors suggest, that HPV-positive HNSCC, being a less agressive 
disease, should be treated with milder therapy regiments (George 2014; Lui and Grandis 
2012). However, until now, therapy is same for both groups (Whang, Filippova, and 
Duerksen-Hughes 2015).   
Survival rates of HNSCC depend on the localisation and stage of the tumor. The best 
survival rates can be expected in laryngeal and nasopharyngeal cancer, independent on 
stage, the worst prognosis can be expected by tumors of the hypopharynx. Relative 
survival negatively correlates with years after diagnosis and stage of the tumor (Greene, 
American Joint Committee on Cancer, and American Cancer Society 2002). 
Stage 1 tumors have the best prognosis with relatively high relative survival rates, 
whereas metastasized carcinoma of the head and neck region is automatically 
categorised as stage IVc and has the worse prognosis. 
1.3.2. Therapy of squamous cell carcinoma of the lung 
The gold standard therapy of early stage NSCLC is anatomical resection (lobectomy, 
segmentectomy, pneumectomy) combined with regional lymph node dissection of 
peribronchial, interlobar, hilar and mediastinal nodes according to recent treatment 
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guidelines (Vansteenkiste et al. 2014; Howington et al. 2013). Sublobular resection has, 
according to recent advances, nearly as good results as anatomical resection in 
peripheral tumors smaller than 2 cm (Vansteenkiste et al. 2014). In inoperable patients 
(medically not fit for an operation) an alternative treatment of choice can be stereotactic 
ablative radiotherapy. 
Cisplatin based adjuvant chemotherapy increases 5-year-survival by 5% in early stage 
NSCLC, although it is not recommended in completely resected stage IA, IB cancer 
(Pignon et al. 2008; Howington et al. 2013). Adjuvant chemotherapy is recommended in 
stage II disease, where an N1 lymph node was positive after pathological staging 
(Howington et al. 2013). 
In stage III NSCLC, therapeutic decision is dependent on many factors and decision 
should be made at multidisciplinary tumor conferences in most cases. Therapeutic 
opportunities include neoadjuvant chemotherapy followed by surgery, as well as 
surgery combined with adjuvant chemotherapy, as well as definitive chemo-
radiotherapy without surgery (Eberhardt et al. 2015). 
In stage IV disease, platinum combinations with docetaxel, paclitaxel, gemcitabine and 
vinorelbine are recommended. If EGFR mutations are diagnosed, afatinib, erlotinib or 
gefitinib should be added to the chemotherapy (Masters et al. 2015). 
EGFR inhibitors can be monoclonal antibodies (cetuximab)  or small molecule tyrosine 
kinase inhibitors (afatinib, erlotinib, gefitinib) and recent research has concluded, that 
they should be used as first-line therapy in advanced EGFR-positive NSCLC (Eberhardt 
et al. 2015). 
According to recent publications the 5-year survival rates of stage 1 and stage 2 NSCLC 
are approximately 60-80% and 40-60%, respectively (Scott et al. 2007; Howington et al. 
2013). 
Compared to stage IVc HNSCC, stage 1 NSCLC has a significantly better prognosis 
according to this data. This underlines the importance of differentiating between 
metastasized HNSCC and early stage NSCLC before choosing the therapeutic protocol.
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1.4. Aims of this study 
The aim of this study was to find out, how precise the combination of clinical and 
routinely used histomorphological and immunohistochemical diagnostic methods are in 
distiguishing between metastatic squamous cell carcinoma and second primary 
squamous cell carcinoma of the lung in patients with squamous cell carcinoma of the 
head and neck region in the patient history. More precisely, our aim was to define 
1. in how many cases are we able to diagnose the origin of the lung tumor using 
human papilloma virus diagnostics; 
2. in how many cases are TP53 gene mutations to be found in the head and neck 
and lung tumors and whether routine mutation analysis would improve 
diagnostic decision making; 
3. whether the results of sequencing all coding exons (2-11) of the TP53 gene are 
superior to sequencing exons 5-8, on which exons the most mutations are to be 
found according to literature; 
4. analyse clinical records to examine therapeutic decision making in cases, in 
which mutational analysis data had not been available; 
5. as well as to find out, whether a combination of human papilloma virus 
diagnostics and TP53 all-exon sequencing and mutation analysis could 
contribute to better therapeutic decision making. 
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2. Materials and methods 
2.1. Materials 
For materials (primers, hardware, kits, consumable materials, reagents, enzymes and 
chemicals) please see the corresponding tables 1-5. 
TP 
53 
Exon 
Forward Primer Sequence Reverse primer Sequence 
2 CCTTCCAATGGATCCACTCACA GTTGGAAGTGTCTCATGCTGGAT 
3 
CCTTACCAGAACGTTGTTTTCAGG CAGGAAACATTTTCAGACCTATGGAAAC 
GATGGGTGAAAAGAGCAGTCAGA GTGGGAAGCGAAAATTCCATGG 
4 
GGATACGGCCAGGCATTGA CCCTGTCATCTTCTGTCCCTT 
GGCATTCTGGGAGCTTCATCTG GAGGACCTGGTCCTCTGACT 
GCTGCCCTGGTAGGTTTTCTG CGATATTGAACAATGGTTCACTGAAGAC 
5 ACAACCTCCGTCATGTGCT CTTTCAACTCTGTCTCCTTCCTCTTC 
6 
GCCACTGACAACCACCCTTAAC GCATCTTATCCGAGTGGAAGGAAA 
GCTAGGCTAAGCTATGATGTTCCTTAGA AAAGAGAGCATGAAAATGGTTCTATGACT 
GGCCAGACCTAAGAGCAATCAG CATGGCCATCTACAAGCAGTCA 
TCATCCAAATACTCCACACGCAAA CTGCTCAGATAGCGATGGTGA 
AGGAAGTAACACCATCGTAAGTCAAG CAATGGCTCCTGGTTGTAGCTA 
7 
TGTGATGAGAGGTGGATGGGTA CCATCCTCACCATCATCACACTG 
GGCTCCTGACCTGGAGTCTT CTCATCTTGGGCCTGTGTTATCT 
8 
CTTGCTTACCTCGCTTAGTGCT GCTTCTCTTTTCCTATCCTGAGTAGTG 
GTGCTAGGAAAGAGGCAAGGAAA GGAAGAGAATCTCCGCAAGAAAGG 
GCTGTTCCGTCCCAGTAGATTAC CTGGAGCTTAGGCTCCAGAAAG 
9 GTGTTAGACTGGAAACTTTCCACTTGA GCAGTTATGCCTCAGATTCACTTTTATC 
10 
TGAGTTCCAAGGCCTCATTCAG CTTTTGTACCGTCATAAAGTCAAACAATTG 
GGCAGGATGAGAATGGAATCCT CGCTTCGAGATGTTCCGAGA 
11 
ACCTATTGCAAGCAAGGGTTCA AGTCCAAAAAGGGTCAGTCTACCT 
CCCTTCTGTCTTGAACATGAGTTTTT CAAAGCATTGGTCAGGGAAAAGG 
Table 1. The list of forward and reverse primer sequences used for targeted next 
generation sequencing of TP53 exons 2-11. 
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Material Type Manufacturer, location 
Automated IHC machine Leica Bond Max Leica, Wetzlar 
Bioanalyzer 2100 Agilent, Santa Clara (CA) 
Centrifuges 5417R 
5415R 
Rotanta/TRC  
Heraeus Biofuge 15R 
 
Heraeus Biofuge Pico 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
Hettich, Tuttlingen 
Thermo Scientific, 
Waltham (MA) 
Thermo Scientific, 
Waltham (MA) 
Enzymatic assay analyzer ELISPot reader AID, Straßberg 
Fluorometer Qubit 2.0 Life Technologies, 
Carlsbad (CA) 
Ion Torrent System Ion OneTouch  
Ion One Touch ES 
Ion Torrent PGM 
Life Technologies, 
Carlsbad (CA) 
 
Light microscope Olympus CX41 Olympus, Tokyo, Japan 
Magnet Invitrogen DynaMag-2 Life Technologies, 
Carlsbad (CA) 
Microtome SM2000R Leica, Wetzlar 
Nucleic acid extraction 
machine 
Maxwell MDx Promega, Madison (WI) 
Pipettes 0.5-10/10-100/100-1000 µl Biohit, Helsinki (Finland) 
Thermocycler Biometra T3000 
 
Labrepco, Horsham (PA) 
Thermomixer F1.5 Eppendorf, Hamburg 
Vacuum oven Memmert Model 400 Memmert, Schwabach 
Vortexer VF2 IKA, Staufen 
Water purification system 
 
Direct-Q 3 Merck Millipore, Billerica 
(MA) 
Table 2. List of hardware (material, type, manufacturer and location). 
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Material Manufacturer, location 
Agilent High Sensitivity DNA Reagents Kit Agilent Technologies, Santa Clara (CA) 
Bond Polymer Refine Detection Kit Leica, Wetzlar 
Cintec Histology Kit Roche, Pleasanton (CA) 
HPV DNA Array Kit AID, Straßberg 
Ion 318 chip Kit Life Technologies, Carlsbad (CA) 
Ion Ampliseq Library Kit 2.0 Life Technologies, Carlsbad (CA) 
Ion Ampliseq p53 Primers 1-2 Life Technologies, Carlsbad (CA) 
Ion OneTouch 200 Template Kit v2 Life Technologies, Carlsbad (CA) 
Ion PGM Hi-Q Reagent Mix Life Technologies, Carlsbad (CA) 
Ion Sphere Quality Control Kit Life Technologies, Carlsbad (CA) 
Ion X-press Barcode Adapters 1-16 Kit Life Technologies, Carlsbad (CA) 
Maxwell 16 FFPE Plus LEV DNA 
Purification Kit 
Promega, Madison  (WI) 
Qubit dsDNA BR Assay Kit Life Technologies, Carlsbad (CA) 
Qubit dsDNA HS Assay Kit Life Technologies, Carlsbad (CA) 
Table 3. List of kits (material, manufacturer and location). 
 
Material  Manufacturer, location 
Cover glasses R Langenbrinck, Emmendingen 
Falcon tubes (15 ml, 50ml) Greiner bio-one, Frickenhausen 
Super Frost slides R Langenbrinck, Emmendingen 
Qubit Assay Tubes Life Technologies, Carlsbad (CA) 
Rainin SR-L10F pipette tips Mettler Toledo, Greifensee 
Rainin SR-L200F pipette tips Mettler Toledo, Greifensee 
SafeSeal Tips (10, 100, 1000 µl) Biozym, Hessisch Oldendorf 
DNA LoBind Tubes (1.5 ml) Eppendorf, Hamburg 
Eppendorf  Safe-Lock Tubes (1,5 ml; 2 ml) Eppendorf, Hamburg 
Table 4. List of consumable materials (material, manufacturer and location). 
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Material Manufacturer, location 
Agencourt Ampure XP Reagent Beckman Coulter, Brea (CA) 
DynaBeads MyOne Streptavidin C1 Life Technologies, Carlsbad (CA) 
Ethanol (absolute) Sigma Aldrich, St. Louis (MO) 
HotStar Taq DNA Polymerase Quiagen, Venlo (Netherlands) 
MgCl2 Quiagen, Venlo (Netherlands) 
Nuclease-free water Life Technologies, Carlsbad (CA) 
Polymerase buffer Quiagen, Venlo (Netherlands) 
Tween 20 Carl Roth, Karlsruhe 
Table 5. List of reagents, enzymes and chemicals (material, manufacturer and location). 
2.2. Methods 
2.2.1. Patients  
Head neck squamous cell carcinomas and synchronous / metachronous squamous cell 
carcinomas of 32 patients between 2011-2016 were compared in our study. The patients 
were aged between 44-72 years at the time of HNSCC diagnosis (median age 61.8 
years). The median time between HNSCC diagnosis and LSCC diagnosis was 17.5 
months. The patient pool was mixed in terms of the primary site of the HNSCC (14 
laryngeal, 8 oral cavity, 5 oropharyngeal, 4 hypopharyngeal, 1 tumor of unknown 
primary). In case of the tumor of unknown primary, the tumor was diagnosed in a 
cervical lymph node. Differentiation between lung metastasis and second primary with 
conventional morphological and immunohistochemical analysis could not be made in 
these cases with certainty (figure 1). The analysis was carried out on formaline fixed 
paraffin embedded (FFPE) specimens (biopsies and resectates) of the tumors. All 
specimens had been obtained during routine diagnostic procedure. The study was 
approved by the ethical committee of the Justus-Liebig University of Giessen (AZ 
105/16).  
2.2.2. Histopathology 
Specimens were formalin fixed and paraffin embedded. 2µm thick sections of the 
routinely processed paraffin blocks were stained with hematoxylin-eosin (HE) and 
examined by an expert pathologist during the routine diagnostic workflow. 
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2.2.3. DNA isolation 
Tumor areas containing more than 30% tumor cells were manually marked under light 
microscope on the hematoxylin-eosin stained slides and the regions of interest were 
manually macrodissected from subsequent 3 µm thick sections for DNA isolation. DNA 
isolation was carried out by the Maxwell 16 System (Promega, Madison, WI) and the 
FFPE LEV DNA Purification Kit (Promega, Madison, WI). 
The specimen was transferred into 180 microliter incubation buffer and 20 microliter 
(20 mg/ml) Proteinase K solution was added. The specimen was incubated overnight on 
70°C, than 400 microliter lysis buffer was added. The solution was vortexed and then 
transferred into the adequate chamber of the Maxwell cartridge for automated 
extraction.  
2.2.4. Concentration determination of the DNA 
DNA concentration determination followed by the Qubit method (Life Technologies, 
Carlsbad, CA). This method is based on marking the DNA with a fluorescent particle 
and comparing the fluorescence to that of standard fluorescent solutions. Two 
fluorescent particles were used depending on the concentration range of the solution – 
the Qubit dsDNA HS Assay Kit (10 pg/µl – 100 ng/µl) and the Qubit dsDNA BR Assay 
Kit (0,1 ng/µl – 1000 ng/µ). For concentration determination 1µl solution was used.   
2.2.5. p16 immunohistochemistry 
Fresh 3 micrometer thick sections were prepared from the FFPE blocks with a 
microtome (SM2000R, Leica, Wetzlar, Germany). Deparaffination was carried out with 
xylene, 100% ethanol, 95% ethanol, 70% ethanol and 50% ethanol 
(immunohistochemistry does only function on deparaffinated material). The slides were 
incubated in hydrogen peroxide to block hydrogen peroxidase activity. The slides were 
immunostained with a primary p16 antibody (clone E6H4 mouse monoclonal, CINtec, 
Ventana Medical Systems, Tucson, AZ) for 20 minutes, than with a secondary rabbit 
anti-mouse IgG antibody (Bond Polymer Refine Detection Kit, Leica Biosystems, 
Nussloch, Germany) for 8 minutes. The reaction was visualized via a brown precipitate 
after adding a polymer Anti-rabbit poly-horseradish peroxidase (HRP) IgG linker 
reagent and a choromogen substrate (3,3’-diaminobenzidine tetrahydrochloride hidrate 
or DAB). Incubation time with the chromogene substrate was 10 minutes. Slides were 
counterstained with hematoxylin to mark nuclei. Staining was carried out using 
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autostaining machines (BOND-III, Leica, Wetzlar, Germany).  The slides were dried in 
a vacuum oven for 30 minutes at 60°C. Stainings were assessed by manually evaluating 
the specific nuclear reaction of the tumor cells (figure 2). 
2.2.6. HPV typing 
The extracted DNA was used to amplify the highly conserved E1 region of the HPV 
genome (if present in the sample) by polymerase chain reaction. The primers used for 
the PCR reaction were biotin labeled consensus primers for the most common HPV 
types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 44, 45, 51, 54, 52, 53, 56, 58, 59, 
66, 67, 68, 69, 70, 73, 82, 85 and 97). For this purpose a HPV DNA kit (HPV DNA 
Array Kit, AID, Straßberg, Germany) was used. The amplification was carried out with 
the HPV Easy-PN-Mix that also contained a primer of the GAP-DH housekeeping gene 
as a positive control of the cellular DNA. 
The reagents used for the PCR-reaction: 
Reagent Quantity 
HPV Easy-PN-Mix 15 µl 
Polymerase Buffer  2.5 µl 
MgCl2 1 µl 
H2O 1.25 µl 
Taq-polymerase 0.25 µl 
Probe 5 µl 
The solution was covered with oil to prevent contamination. 
PCR parameters: 
Time Temperature Cycles 
3 min 95°C 1  
10 sec 96°C 10  
20 sec 60°C 10 
10 sec 95°C 30 
15 sec 55°C 30 
15 sec 72°C 30 
3 min 72°C 
8°C 
1 
∞ 
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After PCR, the quantity of the DNA had to be measured with the Qubit method. 
Optimal concentration of the DNA after PCR amplification was 100 ng/ µl. 
The amplified fragments were than hybridized with sequence-specific oligonucleotide 
probes (SSOP) in a reverse dot blot in situ hybridisation step using a HPV DNA-Array, 
which is a 96-well plate with the SSOPs linked to its bottom. For this purpose, 25 µl of 
denaturation reagent (HPV DNA Array Kit, AID, Straßberg, Germany) was added and 
incubated on room temperature for 30 minutes to create single stranded DNA from the 
double stranded DNA and thus enable hybridisation to the AID plates (AID, Straßberg, 
Germany). 10 µl of the probe and 200 µl hybridisation buffer was than added to the 
wells. The wells were incubated at 47°C for 30 minutes. The supernatant was removed 
and washing steps and addition of the conjugate followed. 
Washing reagent Time Temperature 
Stringent solution 1 min. RT 
Stringent solution 1 min. RT 
Stringent solution 15 min. 47°C 
Rinse solution 1 min. RT 
Rinse solution 1 min. RT 
Conjugate solution 30 min. RT 
Rinse solution (repeat 3x) 1 min. RT 
 
The amplified biotin labeled HPV-DNA (if present) would specifically bind to the 
probes and after a washing step, streptavidin-coupled alkaline phosphatase of the 
conjugate solution bound to the hybrids.  
The conjugate solution consisted of streptavidin coupled alkaline phosphatase (2 µl)  
and conjugate buffer (199 µl). A chromogene substrate (nitroblautetrazolinumchlorid/5-
Brom-4-chlor-3-indoxylphosphat or NBT/BCIP) was added (200 µl, 10 minutes 
incubation on RT) to enable the color reaction. The plates were than washed 2x with 
water and the test could be evaluated.  
Evaluation was semi-automated, using the ELISPot reader (AID, Straßberg, Germany). 
The different HPV serotypes were marked with triplet dots if HPV DNA was present in 
the sample. HPV status was evaluated by half automated detection. 
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2.2.7. Targeted next generation sequencing of the TP53 exones 
Targeted next generation sequencing (NGS) is a powerful high-throughput sequencing 
method based on parallel sequencing of millions of DNA sequences at the same time. 
Using special primer mixes, relatively short (some 100 bp long) frangments of the DNA 
can be amplificated and sequenced in a short period of time. Targeted next generation 
sequencing of exones 2-11 of the TP53 was carried out on the previously extracted 
DNA from the tumor cells of HNSCC and and LSCC using the Ion Torrent platform 
(Life Technologies, Carlsbad, CA, USA) according to the manufacturers instructions. 
The list of the forward and reverse primers is included in table 1. The primer pool 
encompassing the TP53 gene was designed with the Ion Ampliseq Designer tool (multi-
pool design for 175 bp amplicons).  
The sequencing consisted of the following steps:  
1. Preparation of the DNA library 
2. Clonal amplification  
3. Sequencing reaction 
4. Data analysis 
2.2.7.1. Preparation of the DNA library 
After isolation of the DNA, a DNA library had to be prepared. A DNA library consists 
of many DNA fragments of different lengths. The concentration of the DNA isolated 
from the FFPE material was adjusted to 10 ng/microliter using the Qubit concentration 
measurement (see above). A PCR reaction was carried out to amplify the DNA 
fragments of interest. For the first PCR the following reagents were used: 
Reagent Quantity 
2x Ion Ampliseq TP53 Primer Pool (1-2) 10 µl 
5x Ion Ampliseq HiFi Master Mix 4 µl 
genomic DNA, 10 ng 1 µl 
Nuclease-free water ad 20 µl 
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PCR parameters: 
PCR-Step Time Temperature Cycles 
Initial denaturation 2 min. 99°C - 
Denaturation 15 sec. 99°C 20 
Annealing/elongation 4 min. 60°C 20 
Cooling ∞ 10°C - 
 
Our TP53 primer pool consisted of 22 primer pairs.  
The PCR-reaction was followed by a partial digestion of the primer-sequences to enable 
ligation of the adapters, that are essential for the next generation sequencing reaction. 
This was carried out with 2 µl of FuPa reagent (an enzyme mix) to partially digest the 
primers. Incubation was carried out for 10 minutes at 50°C, 10 minutes at 55°C, 20 
minutes at 65°C and finally for 1 hour at 10°C. 
To enable clonal amplification and next generation sequencing, the DNA fragments had 
to be conjugated with two adapters (P1 and a barcode) at the two ends of the fragments. 
The adapter ligation was carried out adding following components to the reaction: 
Reagent Quantity 
Digested Probe 22 µl 
Switch Solution  4 µl 
Ion Ampliseq X-press barcode 2 µl 
DNA ligase 2 µl 
 
Preparation of the X-press barcode mix:  
Reagent Quantity 
P1 adapter 2µl 
X-press barcode 2µl 
Nuclease-free water 4 µl 
 
Because every barcode marks a different probe, probes from many tumors could be 
processed simultaneously in the sequencing process. 
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Incubation of the ligation reagent lasted for 30 minutes at 22°C and then 10 minutes at 
72°C. 
In the next step, the excess of primers and adapters had to be removed. This was carried 
out using magnetic beads that are covered with carboxyl groups and are able to bind 
DNA. Using the beads, the approx. 100 bp long DNA fragments are bound and can be 
washed and once again eluated. For this purpose, the DNA library was transferred in a 
tube after ligation and magnetic beads (45 µl of Agencourt AMPure XP reagent) were 
added to the solution and incubated for 5 minutes.  The incubation was carried out on 
the Dynamag magnets for 3 minutes. Eventually, the beads were washed with 150 µl 
70% ethanol two times and then airdried. The beads (and the DNA library fragments of 
interest now bound to them) were than resuspended in 2 µl Library Amplification 
Primer Mix and 50 µl PCR Supermix High Fidelity solution to carry out library 
amplification. The solution was once again placed on the Dynamag magnets. In this 
step, the DNA dissolved from the beads and were eluated in the supernatant. The 
supernatant was pipetted into a PCR tube. Next, an other PCR reaction followed to 
amplify the DNA library fragments. 
PCR parameters for the DNA-library amplification: 
PCR Step Time Temperature Cycles 
Initial denaturation 2 min. 98°C - 
Denaturation 15 sec 98°C 5 
Annealing/Elongation 1 min. 60°C 5 
Cooling ∞ 10°C - 
 
After the PCR, a second DNA-purification step followed using the magnetic beads (25 
µl of Agencourt AMPure XP Reagent). Incubation lasted again for 5 minutes at room 
temperature and than using the Dynamag magnets for another 5 minutes. The 
supernatant, now containing the amplificated DNA fragments was than pipetted into an 
other tube and 60 µl of the Agencourt AMPure XP Reagent was added once again. The 
solution was incubated using the Dynamag magnets again for another 5 minutes. In this 
step, the approx. 100 bp long DNA fragments bound to the beads. Afterwards another 
washing step followed using 70% ethanol two times. The DNA was resuspended in 50 
µl Low TE and incubated using the Dynamag magnets for 5 minutes.  
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Quantification of the DNA was carried out using the Agilent Bioanalyzer and the 
Agilent High Sensitivity DNA Kit. For DNA quantification, 1 µl of the previously 
prepared DNA library was used. This kit enabled us to visualize the DNA length on a 
virtual gel as well as on an electropherogram and also calculated DNA molarity. For 
this analysis a maximum of 500 pg/µl DNA should be used, therefore concentration 
determination of the DNA library had to be carried out using the Qubit method again. 
When analysing the DNA fragments with the Agilent Bioanalyzer, we should see 
multiple peaks between 125-300 bp. After determination of the molar concentration of 
the DNA library, the end-concentration was adjusted to 100 pM. 
2.2.7.2. Clonal amplification  
The DNA library creation and amplification was followed by the clonal amplification of 
the DNA. For clonal amplification and the following sequencing reaction, the DNA 
fragments had to be bound to the Ion Sphere particles (ISP). The ISP has DNA 
sequences complementary to the adapter sequence P1 (P1 oligo). The library fragments 
can bind to the ISPs and it functions as a primer for amplification. 
During the reaction, the DNA is synthetised and after denaturation the single stranded 
DNA binds to another P1-oligo on the same ISP and the synthesis is repeated. The 
original DNA strand stays bound to the ISP. The synthesis also begins in the reverse 
direction, beginning with the barcode that functions as the reverse primer. Bound to the 
reverse primer is biotin, that enables separation of DNA binding ISPs (positive ISPs 
from negative ISPs) through streptavidin linked magnetic beads. 
The clonal amplification was carried out in form of an emulsion PCR using the Ion 
OneTouch Instrument. The fragments were amplified in oil-enclosed water drops, so 
called microreactors. DNA fragments and ISPs were mixed in an adequate ratio, so that 
statistically only one ISP and one DNA fragment could be found per microreactor. At 
the end of the parallel sequencing, there were millions of ISPs binding the many DNA 
fragments. One ISP had the same DNA fragments in many copies on the surface. The 
amplification solution was prepared as follows: 
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Reagent Quantity 
Ion PGM Hi-Q Reagent Mix 800 µl 
Ion OneTouch Enzyme Mix 50 µl 
Diluted library, 100 pM 25 µl 
Ion OneTouch 200 Ion Sphere Particle 100 µl 
Nuclease-free water 25 µl 
 
The solution was pipetted into the Ion OneTouch Reaction Filter and covered with 1.7 
ml reaction oil. The filter was placed into the Ion OneTouch Instrument and the reaction 
was started. After the emulsion PCR, the ISPs were centrifuged in the Ion OneTouch 
instrument and collected into two reaction tubes. These tubes had been previously filled 
with 150 µl breaking solution. The supernatant was removed and only 50 µl solution 
remained. The ISPs (and bound to them the DNA fragments) were resuspended and 1 
ml Ion OneTouch Wash Solution was added. The ISPs were then centrifuged (2.5 
minutes, 15500 g) and the wash solution was mostly removed (100 µl remained). The 
ISPs were then resuspended in this solution. The negative ISPs were removed using 
magnetic beads paired with streptavidin. This step was automatised and carried out by 
the Ion OneTouch Instrument on an 8-well strip. The strip was filled according to the 
manufacturer’s instructions. 
Well number Reagent to dispense in well 
Well 1 100 µl Entire template-positive ISP sample 
Well 2 130 µL of Dynabeads MyOne Streptavidin C1 
Beads resuspended in MyOne Beads Wash 
Solution 
Well 3 300 µL of Ion OneTouch Wash Solution 
Well 4 300 µL of Ion OneTouch Wash Solution 
Well 5 300 µL of Ion OneTouch Wash Solution 
Well 6 Empty 
Well 7 300 µL of freshly-prepared Melt-Off Solution 
Well 8 Empty 
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The MyOne beads had been washed before this step (13 µl of the beads resuspended in 
130 µl MyOne Beads Wash Solution) and incubated for 2 minutes on the Dynamag 
magnets. The supernatant had been removed and the beads had been once again 
resuspended in 130 µl MyOne Beads Wash Solution.  
The Melt-Off Solution of well 7 was freshly prepared using 125 µl 1 M NaOH, 10 µl 
10% Tween 20 in nuclease free water and 865 µl nuclease free water.   
The purification step was then started and the probes were automatically collected in a 
PCR tube. Afterwards a centrifugation step followed (1.5 minutes, 15500 g). The 
supernatant was removed, until 10 µl solution remained. The Melt-Off Solution had to 
be washed out of the ISPs by adding 200 µl of the Ion OneTouch Wash Solution. The 
ISPs were then once again centrifuged (1.5 minutes, 15500 g). The supernatant was 
once again removed, so that only 10 µl solution remained and it was then diluted to 100 
µl. 
2.2.7.3. Sequencing reaction 
In case of the Ion Torrent Platform, the sequencing reaction is based on the following 
principle: The ISPs with the DNA fragments on their surface are loaded on a chip (Ion 
318 chip). This chip has millions of microwells on its surface, but these wells are so 
small, that only one ISP can fit into one well. When the sequencing reaction is started, 
the chip is flooded with deoxynucleotides in a determined order and if they are 
compatible with the corresponding nucleotide of the DNA fragment, they bind to the 
single stranded DNA on the ISPs with the help of the DNA polymerase. When a 
nucleotide is bound, a protone is released and it leads to a pH change in the well. This 
pH change creates an electronic impulse that can be detected on a protein sensitive plate 
at the bottom of the well. Because of the prior amplification of the fragments, many 
protons are released when a nucleotide is incorporated, so that the pH change is great 
enough to be registered. Should more of the same nucleotides be incorporated in the 
prolonging DNA sequence, the pH change is proportionately greater and can be easily 
registered. It is important to point out, that it might come to reading mistakes when 
sequencing homopolymer repeats (sequences with repeating units). After flooding the 
chip with one nucleotide, the chip is washed and flooded with the next nucleotide. This 
cycle is repeated about 500 times, although more cycles would be needed, when 
sequencing longer fragments. 
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Annealing of IPSs and primers was carried out preparing the following solution: 
positive ISPs (100 µl), Control Ion Sphere Particle (5 µl) and Annealing Buffer (100 
µl). The solution was then centifuged for 1.5 minutes at 15500 g and the supernatant 
was removed except for the last 15 µl. Then 12 µl of sequencing primer was added to 
the solution. The solution was then placed into a thermocycler (2 minutes at 95°C and 
then 2 minutes at 37°C) to promote annealing. After that, 3 µl of the PGM sequencing 
polymerase was added and incubated for 5 minutes on room temperature. The chip was 
set up and the solution was pipetted onto the chip. The sequencing reaction was started 
according to protocols of the manufacturer. 
2.2.7.4. Analysis of targeted next generation sequencing data   
After raw data had been processed by the Ion Torrent Variant Caller software, the 
sequence was compared with the human reference genome (hg19). The single 
nucleotide variations were displayed with the exact localisation of the mutation using 
the Ion Torrent Variant Caller program. To rule out single nucleotide polymorphisms, 
the mutations were compared with an online database (Exome Variant Server, National 
Heart, Lung and Blood Institute, USA).  
The minimal read depth within the region of interest was >1000, mutation frequencies 
had to be >10% to be considered as relevant. 
2.2.8. Assessment  
In case of HPV-positivity of the HNSCC, the lung tumor was classified as a metastasis, 
if it also contained the DNA of the same HPV serotype and was classified as second 
primary LSCC, if HPV negativity was demonstrated. If the HNSCC was HPV negative, 
next generation sequencing of all coding TP53 exones was carried out in the HNSCC 
and in the LSCC and the mutations were compared. In case of similar mutations a 
metastasis, in case of different mutations a second primary lung tumor was diagnosed. 
In case of HNSCC without TP53 mutations, a decision on lung tumor origin could not 
be made, because if the lung tumor contained TP53 mutations, it was not clear, whether 
it was a result of clonal evolution or a second primary LSCC occured. Analysis was 
always carried out with consideration of the histopathological assessment. 
We analyzed clinical records to see, whether the patients were subjected to the best 
possible therapy. We compared the molecular pathological diagnosis with the clinico-
pathological diagnosis. In cases, in which the clinical (radiological) and pathological 
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diagnosis were different, the pathological diagnosis was compared with the molecular 
pathological diagnosis.  
In case of metastases no resection, or wedge resection without lymph node dissection 
was classified as the correct therapy of choice. In case of a second primary LSCC, 
anatomical resections (segmentectomy, lobectomy and pulmonectomy) with regional 
lymph node dissection were assessed as ideal therapy (Howington et al. 2013; 
Vansteenkiste et al. 2014). 
 
  
Results 
30 
 
3. Results  
In our study, 65 tumors of 32 patients were analyzed. In these cases a decision on lung 
tumor origin could not be made using conventional morphological-immunohistological 
methods (figure 1).  
 
Figure 1. There is no difference between HNSCC and LSCC in terms of marker profile and 
morphology irrespective of lung tumor origin. A. HNSCC of patient 23 stained with 
hematoxylin – eosin. Mutation analysis results were included (insert). B. Lung SCC of patient 23 
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stained with hematoxylin – eosin. Mutation analysis results were included (insert). C. HNSCC of 
patient 16 stained with hematoxylin – eosin. Mutation analysis results were included (insert). D. 
Lung SCC of patient 16 stained with hematoxylin – eosin. Mutation analysis results were 
included (insert) (Daher et al. Article in press. 2017).  Abreviations: TP53 = tumor protein 53 
gene. 
At first, HPV status of the tumors was determined using p16 immunohistochemistry and 
HPV typing. After verifying HPV negativity, targeted next generation sequencing of 
exones 2-11 of the TP53 gene was carried out in the HNSCC and LSCC of the patients. 
The data is shown in tables 6 and 7. 
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1 
57 / 
M 
Oropharyngeal / 
T2N2b 
- / - - / - + Metastasis Metastasis No surgery N/A 
2§ 
57 / 
M 
CUP-Syndrome / 
T1aNx 
- / - - / - - 
Primary 
Tumor 
Primary 
Tumor 
Lobectomy with 
lymph node 
dissection 
Curative 
radiation 
therapy of the 
cervical lymph 
node 
3 
61 / 
M 
Oral cavity / 
T1aN1 
+ / - + / - + Metastasis Metastasis No surgery 
Adjuvant 
chemotherapy 
4 
58 / 
M 
Laryngeal / 
T2N2c 
+ / - - / - + Metastasis Metastasis 
Lobectomy with 
lymph node 
dissection 
Palliative 
chemotherapy 
5 
61 / 
M 
Oral cavity / 
T2N0 
- / - - / - - 
Primary 
Tumor 
Primary 
Tumor 
Pneumonectomy 
with lymph node 
dissection 
Adjuvant 
chemotherapy 
6 
57 / 
M 
Hypopharyngeal 
/ TxNx 
- / - - / - + Metastasis Metastasis 
Wedge resection 
without lymph 
node dissection 
Palliative 
chemotherapy 
7 
59 / 
M 
Oropharyngeal / 
TxNx 
+ / - 
N/A 
/ - 
+ Metastasis Metastasis No surgery 
Palliative 
radiotherapy 
8 
44 / 
M 
Hypopharyngeal 
/ T3N1 
- / - - / - + Metastasis Metastasis No surgery 
Radio-
chemotherapy 
9 
54 / 
M 
Laryngeal / 
T2N2b 
+ / - - / - + Metastasis Metastasis No surgery 
Palliative 
therapy 
10 
60 / 
M 
Laryngeal / 
T2N2c 
+ / - - / - - 
Primary 
Tumor 
Primary 
Tumor 
No surgery 
Radiotherapy 
of bone 
metastases 
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11 
61 / 
M 
Laryngeal / 
T2N2b 
- / - - / - + Metastasis Metastasis No surgery Chemotherapy 
12 
57 / 
M 
Oropharyngeal / 
T2N2b 
+ / 
HPV
-16 
+ / 
HPV
-16 
+ Metastasis Metastasis No surgery N/A 
13 
62 / 
M 
Oral cavity / 
TxNx 
- / - - / - - 
Primary 
Tumor 
Primary 
Tumor 
No surgery 
Death 
immediately 
after diagnosis 
14 
57 / 
F 
Laryngeal / 
T2N2b 
- / - - / - - 
Not 
specified 
Primary 
Tumor 
Wedge resection 
without lymph 
node dissection 
No further 
therapy 
15† 
65 / 
M 
CUP-Syndrome / 
TxN2c 
+ / - 
N/A 
/ - 
- 
Primary 
Tumor 
Metastasis 
Lobectomy with 
lymph node 
dissection 
Lobectomy 
(if worsening, 
palliative 
chemotherapy) 
16 
59 / 
M 
Oral cavity / 
T2N1 
- / - - / - - Metastasis 
Primary 
Tumor 
Segmentectomy 
with lymph node 
dissection 
No further 
therapy 
17 
67 / 
M 
Hypopharyngeal 
/ T2N1b 
N/A 
/ - 
N/A 
/ - 
+ 
Primary 
Tumor 
Metastasis 
Pneumectomy 
with lymph node 
dissection 
No further 
therapy 
18 
63 / 
M 
Oral cavity / 
TxNx 
- / - - / - + 
Primary 
Tumor 
Metastasis 
Wedge resection 
with lymph node 
dissection 
Palliative 
radio-
chemotherapy 
19 
56 / 
M 
Oral cavity / 
T1N0 
- / - - / - - 
Not 
specified 
Primary 
Tumor 
Wedge resection 
without lymph 
node dissection 
N/A 
20 
64 / 
M 
Laryngeal / 
T1Nx 
- / - - / - + 
Not 
specified 
Metastasis No surgery 
Palliative 
chemotherapy 
21 
66 / 
M 
Hypopharyngeal 
/ TxNx 
- / - - / - - Metastasis 
Primary 
Tumor 
Segmentectomy 
with lymph node 
dissection 
No further 
therapy 
22 
66 / 
M 
Laryngeal / 
T2N0 
N/A 
/ - 
N/A 
/ - 
+ 
Not 
specified 
Metastasis No surgery 
Death 
immediately 
after diagnosis 
23 
72 / 
M 
Oropharyngeal / 
T2N0 
- / - - / - - 
Not 
specified 
Primary 
Tumor 
Wedge resection 
without lymph 
node dissection 
Palliative 
chemotherapy 
discussed, no 
further therapy 
24 
76 / 
M 
Laryngeal / 
T4bN1 
- / - 
N/A 
/ - 
+ 
Primary 
Tumor 
Metastasis No surgery 
Radiotherapy, 
in case 
chemotherapy 
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25 
67 / 
M 
Laryngeal / 
TxNx 
+ / - - / - - Metastasis 
Primary 
Tumor 
Wedge resection 
without lymph 
node dissection 
Palliative 
chemotherapy 
26 
66 / 
M 
Laryngeal / 
T2N2b 
+ / - - / - - Metastasis 
Primary 
Tumor 
No surgery 
No further 
therapy 
27 
57 / 
M 
Laryngeal / 
T1N1 
- / - - / - - 
Not 
specified 
Primary 
Tumor 
Lobectomy with 
lymph node 
dissection 
No further 
therapy 
28 
65 / 
M 
Laryngeal / 
T2N2b 
- / - - / - + 
Not 
specified 
Metastasis No surgery 
Palliative 
Chemotherapy 
29 
56 / 
M 
Oropharyngeal / 
TxNx 
- / 
HPV
-16 
N/A 
/ - 
N/A Metastasis 
Primary 
Tumor 
No surgery Chemotherapy 
30 
54 / 
M 
Oral cavity / 
T1aNx 
N/A 
/ - 
- / - N/A Metastasis 
Not 
specified 
Wedge resection 
without lymph 
node dissection 
Adjuvant 
chemotherapy 
31 
72 / 
M 
Laryngeal / 
T4aN0 
- / - - / - N/A Metastasis 
Not 
specified 
Wedge resection 
without lymph 
node dissection 
No further 
therapy 
32 
60 / 
M 
Laryngeal / 
T3N0 
- / - - / - N/A 
Primary 
Tumor 
Not 
specified 
No surgery Radiotherapy 
Table 6. Overview of patients showing tumor type, HPV typing results, TP53 mutation 
analysis results (detailed mutational profiling data details shown in table 7), clinicopathological 
data and therapeutic decisions.  HPV-typing enabled differentiation between primary tumor of 
the lung and metastasis in 2 cases (patients 12 and 29), while mutation analysis made a 
differentiation possible in 27 cases. Mutational analysis of exons other than 5-8 was needed for 
a decision in 6 cases. Clinico-pathological diagnoses represent the combination of pathological 
diagnosis and clinical diagnosis made without knowledge of the molecular genetic data. If 
clinical and pathological diagnosis were different, the pathological diagnosis was compared with 
the molecular genetic diagnosis. Clinico-pathological diagnoses matched the molecular 
pathological diagnosis in 13 cases (green highlight), while clinico-patholgical diagnoses differed 
from the molecular pathological diagnosis in 16 cases (red highlight). In patients 30-32, a 
molecular pathological diagnosis was not possible, because no TP53 mutations were detected 
in the HNSCC (grey highlight) § Patient 2 was diagnosed with a cervical lymph node infiltration 
adherent to his lung tumor. Surprisingly, all three tumors (head and neck, lymph node and lung) 
harbored different TP53 mutations, therefore it was concluded that the cervical lymph node was 
infiltrated by a cancer of unknown primary. Curative resection of the lung tumor and curative 
radiation of the cervical lymph nodes was carried out. † Patient 15 had different mutations in the 
lymph node metastases of an unknown primary tumor and the lung tumor, but the 
morphological histological pattern was very suggestive of a metastasis, so that a lung 
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metastasis of an unknown head and neck primary tumor was diagnosed (Daher et al. Article in 
press. 2017). 
Patient 
Number 
TP53 Mutation 
HNSCC 
TP53 Mutation 
LSCC 
1 c.993+1G>A splice donor intron 9 
inactivation 
c.993+1G>A splice donor intron 9 
inactivation 
2§ c.661G>T p.E221X (HNSCC); 
c.166G>T p.E56* (Cervical lymph 
node) 
c.811G>T p.E271* 
3 c.524G>A p.R175H c.524G>A p.R175H 
4 c.725G>A p.C242Y c.725G>A p.C242Y 
5 c.892G>T p.E298 c.672+1G>A splice donor  
intron 6 
6 c.538G>T pE180* c.538G>T pE180* 
7 c848G>C pR283P c848G>C pR283P 
8 c.916C>T pR306* c.916C>T pR306* 
9 c.476 C>T p.A159V c.476 C>T p.A159V 
10 c.217_219 delinsGT P.P72fs; c.824 
G>A pC275Y 
No mutation 
11 c.574 C>T p.Q192* c.574 C>T p.Q192* 
12 N/A N/A 
13 c.332T>A p.L111Q c.818G>T p.R273L 
14 c.892G>T p.E298X; c.464C>A 
p.T155N 
c.1.010G>C p.R337P 
15 c.597delA p.G199fs c.818G>T p.R273L 
16 c.338T>G p.F113C c.775G>T p.D259Y 
17 c.476C>A pA159D c.476C>A pA159D 
18 c.659A>G p.Y220C c.659A>G p.Y220C 
19 c.161delT p.F54fs c.535C>G p.H179D 
20 c.517G>T p.V173L; c.35G>T p.G12V c.517G>T p.V173L; c.35G>T p.G12V 
21 c.713G>T p.C238F No Mutation 
22 c.844 C>T p.R282W c.844 C>T p.R282W 
23 c.482_485dup pA161fs c.625A>T p.R209* 
24 c.1024C>T p.R342* c.1024C>T p.R342* 
25 c.659A>G p.Y220C No mutation 
26 c.1005_1006ins 
TGC,GGG,TGC,CTA,GG  
p.R335fs 
No mutation 
27 c.733 G>T p.G245C; c.447delC 
p.149fs 
c.301_314del p.K101fs 
28 c.844 C>T p.R282W c.844 C>T p.R282W 
29 N/A N/A 
30 No mutation No mutation 
31 No mutation No mutation 
32 No mutation c.742C>T p.R248W 
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Table 7. Mutational profiling data in samples from head and neck squamous cell 
carcinoma (HNSCC) and corresponding lung squamous cell carcinoma (LSCC). § Patient 
2 was diagnosed with a cervical lymph node infiltration adherent to his lung tumor. Mutations 
are shown for all three tumors (Daher et al. Article in press. 2017). 
p16 immunohistochemistry could be successfully performed with 55 tumors (figure 2). 
In case of 10 tumors, there was not enough tumor material available for both p16 
immunohistochemistry and HPV typing analysis, so that in these cases HPV typing was 
prefered. 11 tumors (20%) showed p16 positivity, although HPV positivity could be 
shown in only two of these cases using HPV typing.  
 
Figure 2. Positive immunohistochemical staining of p16 (brown stain) in a laryngeal 
resectate (patient 10). Nuclei were counterstained with hematoxylin (blue stain). Scale bar 200 
µm. Abbreviations: p16 = protein 16 (Daher et al. Article in press. 2017). 
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HPV typing showed HPV positivity in 3 tumors of two patients (patient 12, 29). Every 
other analyzed tumor turned out to be HPV negative. A decision on lung tumor origin 
could be made in 2 of 32 cases (6%) using HPV analysis only.  
Targeted next generation sequencing of the TP53 coding exones in 61 tumors of the 30 
remaining patients found 57 mutations in 54 tumors. Mutations on exones 5-8 were 
detected in 43 of the 57 cases (75%). Mutations on exones 2-4 and 9-11 were found in 
14 cases (25%). Data included in figure 3. Diagnosis of the LSCC origin depended on 
all-exon sequencing in 6 of 32 cases (19%).  
 
Figure 3. TP53 gene mutation distribution on exones 2-11 in the examined tumors. The 
mutations located on the splice donor and acceptor sites of the introns adherent to the exon 
were counted with the respective exon mutations. 25% of mutations were located outside of 
exones 5-8. This stresses the importance of analysis of all coding exones (Daher et al. Article in 
press. 2017). 
Of the 57 mutations, 47 were substitutions (11 leading to nonsense mutations), 3 splice 
donor site mutations, 1 duplication, 1 insertion and 5 deletions (one combined with an 
insertion). 
Identification of lung tumor origin was achieved in 29 of 32 cases (90%) using a 
combination of HPV typing and TP53 mutation analysis. 
In case of patient 2, three tumors (head and neck squamous cell carcinoma, cervical 
lymph node metastasis of a squamous cell carcinoma and lung squamous cell 
carcinoma) were compared. It turned out, that all three tumors harbored different 
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mutations, so that a primary lung tumor and a cancer of unknown origin (CUP) were 
diagnosed.  
In case of patient 15, different mutations were found in a cervical lymph node 
metastasis of a squamous cell carcinoma and in the lung squamous cell carcinoma. 
However, the growth pattern of the lung tumor was so suggestive for a metastasis, that a 
lung metastasis of a cancer of unknown primary and a lymph node metastasis of another 
primary were diagnosed. 
The analysis of clinico-pathological diagnoses and comparison with the molecular 
pathological diagnoses revealed that a correct evaluation of lung tumor origin had only 
been possible in 13 out of 29 cases (45%) based on clinical and morphological data 
alone. In 16 cases clinicopathological and molecular pathological diagnosis were 
discrepant, and in three cases a molecular pathological diagnosis was not possible, 
because there were no mutations detected in the head and neck tumors (table 6). 
 Analysis of the surgical treatments showed that 11 out of 23 patients (48%), in whose 
case surgical resection had been carried out before mutational profiling, had not 
received the most suitable treatment: 3 patients (4, 15, 17) with pulmonary HNSCC 
metastases were subjected to extensive resections (pulmonary lobectomy or 
pneumectomy with excision of regionary lymph nodes), (figure 4, patient 17), while the 
second primary LSCC of 8 patients (10, 14, 19, 23, 25, 26, 29) were not excised 
radically (Table 6). In contrast, availability of HPV typing and mutational profiling data 
made it possible, that all patients got the most suitable therapy (table 6; figure 4, patient 
16).  
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Figure 4. Therapeutic consequences of surgical resection of the lung tumor on two 
representative cases. Patient 7 had a pT1a primary lung squamous cell carcinoma diagnosed 
1 month after the diagnosis of his HNSCC, mutation status was confirmed by TP53 mutation 
analysis. The therapy of choice was segment resection with regional lymph node dissection. 
Patient 9 had a lung squamous cell carcinoma diagnosed 54 months after diagnosis of his 
HNSCC. Mutation analysis was not carried out on a biopsy, the right upper lobe was rather 
resected accompanied by regional lymph node dissection. A. Computed tomography image of 
the lungs of patient 7 at the time of lung tumor diagnosis. B. Computed tomography image of 
the lungs of patient 7, 9 months after surgical resection of the lung tumor. No sign of further 
tumors.  C. Computed tomography image of the lungs of patient 9 at the time of lung tumor 
diagnosis. D. Computed tomography image of the lungs of patient 9, 7 months after resection of 
the left upper lobe. Several newly diagnosed tumors in the right lung. This stresses the 
importance of mutation analysis already on the biopsy material before resection. The orange 
arrows point at the lung tumors (Daher et al. Article in press. 2017). 
 
  
Discussion 
39 
 
4. Discussion  
In our study 65 head and neck squamous cell carcinomas and lung squamous cell 
carcinomas of 32 patients were analysed. In our experience, using only traditional 
morphological / immunohistochemical diagnostics, patients with head and neck 
squamous cell carcinoma and synchronous / metachronous lung squamous cell 
carcinoma pose an unsolvable diagnostic challenge in the pathological diagnostic 
routine. However, as therapeutic protocols and patient outcomes are potentially 
different in patient groups with metastasized HNSCC and low stage second primary 
LSCC, a reliable diagnostic method would be essential to differentiate between them.  
We combined p16 immunohitochemistry and HPV typing to compare HPV status of the 
tumors in the hope to differentiate between metastasis and second primary tumor in the 
lung. In case of a HPV negativity in both HNSCC and LSCC we performed a targeted 
next generation sequencing of all coding exones (exon 2-11) of the TP53 gene to 
compare mutation status. With the use of HPV analysis, a decision on lung tumor origin 
could have been made in only 2 of the 32 cases (6%). With the use of targeted next 
generation sequencing of all coding exones we could make a decision in 29 of 32 cases 
(90%). Without the use of molecular methods a diagnosis could have only been reached 
in 13 of 29 cases (45%). According to our results 25% of the mutations were found to 
be localised outside of the most often examined exones 5-8, and diagnosis on LSCC 
origin in 6 of 32 cases (19%) depended on all-exon sequencing. This stresses the 
importance of analysing all coding exones when searching for mutations.  
The analysis of the pathology reports showed, that diagnostic criteria for lung tumor 
origin determination are inconsistent. The decisions in the pathological decision making 
depended on tumor growth pattern or immunohistochemical phenotype. Furthermore, 
clinical decision making depending on radiology reports was also inconsistent. We 
concluded, that the origin of lung tumors had only been identified correctly in 45% of 
the cases based on clinical and morphological data alone. Analysis of the administered 
surgical treatments showed that more than almost 50% of patients, where mutation 
analysis data had not been available, had not received the most suitable treatment.  In 
this study we conclude, that traditional histomorphological analysis is not sufficient in 
these cases and the use of molecular diagnostics is indispensable.   
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In countries, where tendentially less individuals are smoke, the prevalence of HPV-
associated head and neck cancer has been growing in the last decades (Chaturvedi et al. 
2008; Ryerson et al. 2008). HPV testing of head and neck cancer has become part of the 
routine diagnostics. This is an important aspect, because the prognosis of HPV positive 
disease is better, than that of HPV negative disease (Fakhry et al. 2008; Licitra et al. 
2006; Weinberger et al. 2006). 
An important question of HPV analysis is the method of choice. The possibilities are 
overwhelming, but choosing the right method needs some consideration. According to 
recent literature, a combined analysis with immunohistochemistry and in situ 
hybridisation gives a highly precise information on the HPV status of the tumor (Marur 
et al. 2010b; Singhi and Westra 2010).   
It should be pointed out, that p16 positivity might occur in HPV negative cases. In our 
case it happened in 20% of the cases. This underlines the importance of combined 
testing. 
It has been described by other authors, that 20% of LSCC tested positive for HPV in 
patients with HNSCC in the clinical history (Bishop et al. 2012). In an other study of 
HNSCC and female genital tract cancer patients with a following LSCC, concordant 
HPV status was found in 14.2% and different HPV status was found in 42.9% of the 
cases. A decision depending on HPV status of the tumors could be made in 57.1% of 
the cases (Weichert et al. 2009).  
However, if both tumors turn out to be negative and also in patient collectives with less 
HPV-associated tumors, additional methods should be considered.  
Some authors favorised a microsatellite analysis of the chromosomes 3p and 9p and 
could decide on LSCC origin in 13 of 16 cases in one study (Leong et al. 1998).  In a 
further study, loss of heterozygosity (LOH) analysis of several chromosomes was 
carried out for differentiation between lung metastasis and second primary in HNSCC 
patients and the method could be successfully used in 43 of 44 analysed cases (Geurts et 
al. 2005).  
The LOH method has also been combined with a PCR based single-strand conformation 
polymorphism assay of exon 5-8 of TP53 and this study also showed, that a correct 
diagnosis impacts further therapy in a patient collective with different primary and 
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secondary tumors. In some of the analysed cases the patients had a HNSCC as a 
primary and a LSCC as a secondary tumor (van der Sijp et al. 2002).   
These works show, that although the gold standard method has been debated, TP53 
analysis has been widely used for tumor origin determination. TP53 mutations have 
been described as very good clonal markers because of their stability during metastasis 
and variability of mutations (van Oijen et al. 2000; Tabor, van Houten, et al. 2002), 
which make the analysis of the TP53 gene a feasible marker for mutation analysis when 
looking for secondary tumor origin (Tabor, Brakenhoff, et al. 2002; Hittelman 2001; 
Brennan et al. 1995; van Houten et al. 2002; Califano et al. 1999; Garcia et al. 1999). 
The discussed studies concluded, that finding the same mutations / genetic alterations in 
two different tumors point to a metastasis, whereas different mutations / genetic 
alterations suggest a second primary tumor. HNSCC have been described to be clonally 
stable in terms of TP53 mutations. However, most works discussing this question 
mostly used sequencing of exones 5-8 mostly because of technical reasons. 
According to literature and also our own results presented here, mutations localised on 
exons 2-4 and 9-11 are also to be expected (Saunders et al. 1999; Hartmann et al. 1995). 
This makes all-exon sequencing particularly important in these cases.  
It would be indispensable to find a diagnostic tool to differentiate between metastasis 
and second primary LSCC in patients with HNSCC in the clinical history, because 
therapeutic concepts in the two cases might be radically different (as discussed in the 
corresponding part of this work). In case of individuals with a low stage primary 
squamous cell carcinoma of the lung, a curative radical resection with lymph node 
dissection should be favorised (Howington et al. 2013; Vansteenkiste et al. 2014). In 
metastatic cases radical resections should not be carried out, because it might 
unnecessarily impair respiratory function. On the other hand, patients with second 
primary LSCC should not be categorised as metastatic and get subjected to palliative 
therapy. Our results listed here show that our diagnostic setting can be used to reach a 
diagnostic decision in the majority of the cases and lead to improved clinical decisions.  
Further analysis of the survival statistics of the patients would be needed at a later 
timepoint to confirm, that patient groups with metastatic disease and low stage second 
primary lung carcinoma have different prognosis. 
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In cases, in which a diagnostic decision could not be made because there was no TP53 
mutation to be found in the head and neck tumor, analysis of a larger group of relevant 
genes should be considered. With recent advances in the discovery of tumor relevant 
genes and better understanding of the genetics of these tumors and because of the 
spread of next generation sequencing technology it is possible that all tumors be 
categorised as metastasis or second primary, promoting personalised therapy of the 
patients. 
 
 
*** 
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5. Summary 
Head and neck squamous cell carcinoma (HNSCC) is a malignant epithelial disease 
arising from the mucosa of the upper aerodigestive tract. It is the 6th most common 
malignancy worldwide with approximately 650 000 new cases diagnosed each year. In 
patients with HNSCC, the chance of acquiring a second malignancy in the lung is about 
5.4%. Differentiation between a lung metastasis of a HNSCC and a second primary 
squamous cell carcinoma of the lung (LSCC) remains one of the most difficult tasks in 
diagnostic pathology, although differentiation would be crucial because of the highly 
different therapeutic regimes. In most cases traditional morphological examinations fail 
to find the origin of the lung tumor, so that a reliable method of differentiation is 
desperately needed. Differentiation has to be made between two major types of 
HNSCC; HPV-associated and non-HPV-associated tumors which are caused by tobacco 
smoking and alcohol consumption and harbor TP53 mutations in most of the cases. 
Researchers have tried to differentiate between lung metastasis and second primary 
comparing HPV-status of the head and neck and the lung tumors with some success, but 
in case of negativity of both tumors further analysis is needed. In the past few years, 
next generation sequencing technology (NGS) has been established worldwide and also 
in our institute of pathology. This method has the advantage, that mutations of all 
coding exones of the TP53 gene can be examined in a time-effective high-troughput 
way. We hypothetised, that comparing the mutations of the HNSCC and LSCC can lead 
to a decision on lung tumor origin. In our study 65 head and neck squamous cell 
carcinomas and lung squamous cell carcinomas of 32 patients were analysed. We 
combined p16 immunohitochemistry and HPV typing to compare HPV status of the 
tumors in the hope to differentiate between these two entities in the lung. In case of 
HPV negativity in both tumors we performed a targeted next generation sequencing of 
all coding exones (exon 2-11) of the TP53 gene to compare mutation status. With the 
use of HPV analysis only, a decision on lung tumor origin could be made in 2 of the 32 
cases (6%). With the use of targeted next generation sequencing of all coding exones of 
the TP53 gene we could make a decision in 29 of 32 cases (90%). Analysis of clinical 
records showed, that lung tumor origin has been identified correctly in only 13 out of 29 
cases (45%). Furthermore, 11 out of 23 patients (48%) for whom mutational profiling 
data had not been available, had not received the most suitable treatment. We conclude, 
that NGS of all TP53 exones in these tumors can lead to better therapeutic decisions. 
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6. Summary (german version) 
Das Plattenepithelkarzinom der Kopf-Hals-Region (HNSCC) ist eine maligne 
epitheliale Erkrankung ausgehend von der Mukosa des oberen Aerodigestivtraktes. Es 
ist die 6. häufigste maligne Erkrankung weltweit mit ca. 650000 neu diagnostizierten 
Fällen jährlich. Etwa 5,4% der Patienten mit HNSCC entwickeln Zweitmalignome in 
der Lunge. Unterscheidung zwischen einer Lungenmetastase und einem zweiten 
Primarius in der Lunge (LSCC) bleibt eine der schwierigsten Aufgaben in der 
diagnostischen Pathologie. Dabei wäre eine Abgrenzung der beiden Entitäten 
voneinander entscheidend, da die Therapieprotokolle verschieden sind. In den meisten 
Fällen können morphologische Untersuchungen die Herkunft des Lungentumors nicht 
identifizieren, deswegen ist eine vertrauliche diagnostische Methode zwingend 
notwendig. Es muss zwischen zwei Haupttypen von Tumoren unterschieden werden: 
HPV-assoziierten und nicht-HPV-assoziierten Tumoren. Die letzteren werden durch 
Rauchen und Alkoholkonsum verursacht und sind häufig mit TP53 Mutationen 
assoziiert. Einige Autoren haben versucht, zwischen einer Metastase und einem zweiten 
Primarius anhand des HPV-Status zu differenzieren. Bei HPV-Negativität im HNSCC 
und LSCC sind aber weitere diagnostische Maßnahmen notwendig. In den letzten 
Jahren wurde die Sequenzierung der neuen Generation (NGS) weltweit und auch in 
unserem Institut für Pathologie etabliert. Diese Methode hat den Vorteil, dass alle 
kodierenden Exone des TP53 Gens mit hohem Durchsatz und zeiteffektiv sequenziert 
werden können. In unserer Studie haben wir 65 HNSCC und LSCC von 32 Patienten 
verglichen. Wir haben p16 Immunohistochemie und HPV-Typisierung kombiniert, in 
der Hoffnung, dass wir zwischen den zwei Entitäten in der Lunge differenzieren 
können. Im Falle einer Negativität in dem HNSCC und LSCC haben wir eine targetierte 
Next-Generation-Sequenzierung der kodierenden Exone (Exon 2-11) des TP53 Gens 
durchgeführt, um den Mutationsstatus zu vergleichen. Mit der HPV-Analyse konnten 
wir nur in 2 von 32 Fällen (6%) eine Entscheidung bezüglich der Herkunft des 
Lungentumors treffen.  Mit targetierter NGS konnten wir in 29 von 32 (90%) Fällen 
eine Entscheidung treffen. Die Analyse der klinischen Daten zeigte, dass die Herkunft 
des Lungentumors nur in 13 von 29 Fällen (45%) korrekt angegeben wurde. 
Dementsprechend wurden 11 von 23 (48%) Patienten ohne vorheriger Mutationsanalyse 
nicht laut Leitlinien therapiert. Wir schlussfolgern daraus, dass NGS von allen 
kodierenden TP53 Exonen zu besseren therapeutischen Entscheidungen führen kann.
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ABSTRACT 
Background: In head and neck squamous cell carcinoma (HNSCC), the occurrence of 
concurrent lung malignancies poses a significant diagnostic challenge because metastatic 
HNSCC is difficult to discern from second primary lung squamous cell carcinoma (LSCC). 
However, this differentiation is crucial because the recommended treatments for metastatic 
HNSCC and second primary LSCC differ profoundly. 
Methods: We analyzed lung tumors origin in 32 HNSCC patients using human papilloma virus 
(HPV) typing and targeted next generation sequencing of all coding exons of tumor protein 53 
(TP53). 
Results: Lung tumors were clearly identified as HNSCC metastases or second primary tumors 
in 29 patients, thus revealing that 16 patients had received incorrect diagnoses based on clinical 
and morphological data alone. 
Conclusions: HPV typing and mutation analysis of all TP53 coding exons is a valuable 
diagnostic tool in patients with HNSCC and concurrent LSCC which can help to ensure that 
patients receive the most suitable treatment. 
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einem Hypopharynxkarzinom in der Vorgeschichte: Metastase oder zweiter Primarius? 
101. Tagung der Deutschen Gesellschaft für Pathologie (2017), congress contribution 
in german language. 
ABSTRACT 
Anamnesis: A pulmonary neoplasm of the left lung has been incidentally described in a 
72 year old male patient. The patient had been diagnosed with a hypopharingeal 
squamous cell carcinoma 54 months earlier. The hypopharyngeal tumor had been 
successfully resected (Tumorstadium: pT2, pN2b (2/39), L0, V0, G3, R0). A CT-guided 
biopsy of the neoplasm followed. On the biopsy material a squamous cell carcinoma 
was diagnosed in an external institution. The therapy of choice was pneumectomy 
combined with regional lymph node dissection. 
Examinations: Using conventional histomorphological methods it was not to decide, 
whether it is a metastasis of the laryngeal carcinoma or a second primary squamous cell 
carcinoma of the lung. To find it out, a comparative HPV analysis and after that targeted 
next generation sequencing of the coding exones of the TP53 gene was carried out in 
both tumors. 
Diagnosis, therapy and clinical course: The mutation analysis showed the same 
mutations in the head and neck and in the lung tumor. Corresponding to this, seven 
months after the lung tumor resection, further metastases were discovered in the 
contralateral lung. 
Conclusion: Therapy of low stage primary squamous cell carcinoma and metastatic 
squamous cell carcinoma is drastically different. In metastatic cases a radical resection 
of the lung tumor is not indicated. In case of newly diagnosed pulmonary neoplasms in 
patients with head and neck squamous cell carcinoma in the patient history a molecular 
pathological analysis should be carried out already on the biopsy material before 
resection, if possible. This may help to differentiate between lung metastasis and second 
primary and help to guide therapeutic decisions.  
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